Red Light Therapy for Arthritis: What the Studies Show
Share
Red Light Therapy for Arthritis: What the Studies Show
I haven't taken a single painkiller in over a year.
I want to say that plainly because I know how it sounds. It sounds like the kind of thing someone writes on a supplement ad. It's not. My ankle has given me grief for years — the kind of grinding, morning-negotiation arthritis where you're doing a slow inventory of what's going to cooperate before your feet even hit the floor. Through a full Norwegian summer. Through a winter that was particularly brutal on the joints. Through months of walking more than I should have, and carrying my daughter around when she decided her legs had stopped working mid-trip. Not one painkiller. Less stiffness. Less swelling. Less pain.
Red light therapy (rødlysterapi) has a substantial and growing body of clinical research supporting its use for arthritis and joint inflammation. A review of 18 double-blind trials on photobiomodulation in chronic rheumatoid arthritis patients found significant improvement in both acute small joint inflammation and chronic pain, with an 80% success rate in relieving pain. Separate research involving 170 patients with rheumatoid arthritis using photobiomodulation showed pain reduction of up to 90% in responding participants.
Those numbers stopped me the first time I read them properly. 80% success rate across 18 properly controlled trials. That's not a promising pilot study. That's a consistent, replicated finding across a large body of work. And yet most people with arthritis have never been told this is an option.
Why light works on inflamed joints
The mechanism isn't mysterious, it's just not widely explained. Your joint tissue — the synovium, the cartilage, the surrounding connective tissue — is metabolically active and highly responsive to specific wavelengths of red and near-infrared light. When red light (around 630-680nm) and near-infrared light (around 800-850nm) penetrate the tissue, they're absorbed by cytochrome c oxidase, the primary light-absorbing protein in your mitochondria.
What happens next is what matters for arthritis specifically. ATP production increases. Reactive oxygen species levels drop. Nitric oxide — which is displaced from cytochrome c oxidase under inflammatory conditions — gets released, improving local blood flow. The net effect is a reduction in the pro-inflammatory cytokines that are driving your pain and swelling, and an upregulation of the anti-inflammatory pathways your body uses to repair tissue.
You can read the mechanism explained in detail in this 2017 paper on the anti-inflammatory effects of photobiomodulation: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5523874/
The cartilage and synovial tissue respond specifically because the mitochondrial density in those cells is high and the light penetration at near-infrared wavelengths is sufficient to reach them. That's the answer to "but how does light get deep enough?" — near-infrared at 850nm penetrates several centimetres into tissue. It reaches the joint.
What the clinical research actually shows
The evidence base for red light therapy and arthritis is substantial. These aren't fringe studies. They're published in peer-reviewed journals and indexed in the National Library of Medicine.
A 2014 paper in Photomedicine and Laser Surgery asked whether osteoarthritis can be treated with light — you can read it here: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978432/
A meta-analysis of low level laser therapy for osteoarthritis and rheumatoid arthritis, covering multiple trials, found consistent evidence of benefit: https://www.ncbi.nlm.nih.gov/pubmed/10955339
And for anyone who wants to go deeper into how inflammatory cytokine production in rheumatoid arthritis synoviocytes responds to photobiomodulation, this 2009 paper is directly relevant: https://www.ncbi.nlm.nih.gov/pubmed/19347944
A 2004 systematic review specifically examined location-specific dosing for chronic joint disorders and found that with correct parameters, pain relief was consistent across study populations: https://www.ncbi.nlm.nih.gov/pubmed/12775206
Research has also demonstrated improvements in cellular rejuvenation and local blood flow, and reductions in oxidative damage to joint tissue. Oxidative damage is a major driver of cartilage degeneration — reducing it means less destruction of the tissue over time, not just symptomatic relief. That's a meaningful distinction if you're thinking about this as a long-term strategy rather than a one-time fix.
Does that match your experience of what you've been told about managing arthritis? Probably not. Most people are handed anti-inflammatories and told to manage expectations. The research suggests there's another option worth knowing about.
The biphasic dose response — why this part matters
Almost nobody selling red light panels in Norway talks about this, and I think that's a problem.
Photobiomodulation follows what's called the Arndt-Schulz curve, or biphasic dose response. The right amount of light stimulates healing. Too little does nothing. Too much — and this is the part people miss — can actually inhibit the very response you're trying to create. This is documented clearly in the research (Hamblin et al., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2790317/).
What this means practically is that "5-20 minutes, 3-7 times per week" — the standard advice you'll find most places — is not a protocol. It's a guess. The correct dose depends on the irradiance of your device at the distance you're using it, the specific tissue you're treating, and how your body is responding. A joint has different light absorption characteristics to skin or superficial muscle.
I've seen people overdose on sessions — more, more, more — and wonder why they're not seeing results or why things have temporarily got worse. More is not always better. The Goldilocks zone is real, and finding it for your situation matters.
If you want to go deeper on why dosing is the piece most companies won't discuss, I wrote about it here: https://lighttherapy.no/blogs/english/why-the-right-dose-of-red-light-therapy-matters-many-companies-wont-tell-you-this
Results aren't guaranteed — and that's important to say
I am one of the 80%. I want to be clear about that framing because the honest version of this conversation acknowledges the 20% too.
A woman contacted me not long after she'd bought a panel. She had ankylosing spondylitis and hadn't been able to put on her own socks for over a year. A few weeks after starting, she messaged me in tears — she'd managed it for the first time. Then she overdid the sessions, had a setback, felt like it had stopped working. We recalibrated her protocol together. She found her rhythm. She's doing well now. The result was real — but the path wasn't linear and the dose mattered enormously.
That story is why I ask people to get in touch before and after they start. Not to upsell them on something. To help them get the protocol right so they're in the 80%, not spending months confused about why it's not working.
I also want to be straight with you about the research variables. The studies on photobiomodulation and arthritis use different devices, different wavelengths, different dosing protocols, different patient populations. That's why results vary. The good news is that the direction of the evidence is consistent. The detail is in the parameters.
For a fuller breakdown of what the research on joint pain looks like in practice, including what I've seen working with customers here in Norway, read this: https://lighttherapy.no/blogs/english/red-light-therapy-joint-pain-arthritis-norway
For us in Norway specifically
Winter is genuinely harder on arthritic joints. If you live here you know this without me explaining it. The cold constricts blood vessels, reduces circulation to peripheral tissue, and the absence of solar infrared during the dark months means your tissue is missing the natural photonic input that supports mitochondrial function. Your joints feel worse in January and February not just because it's cold — it's also because the light that supports cellular repair has been absent for months.
Red light therapy is not a substitute for sunlight. But in November through March, when the sun barely clears the horizon and you're not getting any meaningful solar infrared on your skin, it fills a real gap. That's not marketing language. It's biology.
If you want to look at panels suited for joint targeting — devices with sufficient near-infrared output to reach the tissue — the collection is here: https://lighttherapy.no/collections/red-light-panels
And if you're not sure which device makes sense for your specific situation, message me directly. That's what I'm here for.
This post is educational and not medical advice. Red light therapy is not a replacement for treatment from a qualified medical professional. If you have rheumatoid arthritis or another autoimmune joint condition, discuss any new interventions with your doctor.
FAQ
Does red light therapy actually help with arthritis pain, or is it just placebo?
The clinical evidence is not consistent with a placebo explanation. A review of 18 double-blind placebo-controlled trials found an 80% success rate in pain relief for chronic rheumatoid arthritis patients using photobiomodulation. Double-blind design controls for placebo effect by definition. The mechanism — reduced inflammatory cytokine production, increased ATP synthesis in joint tissue, improved local circulation via nitric oxide release — is well-documented at the cellular level. That doesn't mean it works for everyone, but the evidence base is substantially stronger than most people are aware of.
How long does it take to notice a difference using red light therapy for joint pain?
This varies considerably depending on the severity of the condition, the device being used, and whether the protocol is well-matched to the tissue being treated. Some people notice reduced stiffness within the first week of consistent use. Others take four to six weeks to see meaningful change. Chronic conditions that have been present for years typically take longer to respond than acute inflammation. The biphasic dose response also matters here — too much or too little light produces suboptimal results, so getting the protocol right affects how quickly you see results.
Can I use red light therapy alongside my current arthritis medication?
There is no known negative interaction between photobiomodulation and standard arthritis medications, including NSAIDs, DMARDs, or biologics. Many people use it alongside existing treatment as an adjunct rather than a replacement. That said, this is a conversation to have with your prescribing doctor, particularly if you are on immunosuppressant therapy, as they will know the specifics of your case.
Kan rødt lysterapi hjelpe med leddgikt om vinteren i Norge?
Ja, og det er faktisk særlig relevant i norske vintermåneder. Kulde reduserer blodsirkulasjonen til perifere vev og forverrer stivhet og smerte hos mange med leddgikt. Samtidig er vi i Norge i store deler av vinteren uten meningsfull soleksponering, noe som betyr at kroppen mangler den naturlige infrarøde strålingen som støtter mitokondriell funksjon i vevet. Rødlysterapi (rødlysterapi) kan kompensere for noe av dette tapet ved å stimulere cytokrom c oksidase direkte i leddbetennelsen, redusere pro-inflammatoriske cytokiner og øke lokal blodsirkulasjon via nitrogenoksid. Det er ikke en erstatning for medisinsk behandling, men forskningen støtter det som et nyttig tillegg.
References
- Anti-inflammatory effects of photobiomodulation: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5523874/
- Can osteoarthritis be treated with light: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978432/
- Low level laser therapy for osteoarthritis and rheumatoid arthritis meta-analysis: https://www.ncbi.nlm.nih.gov/pubmed/10955339
- Biphasic dose response in low level light therapy: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2790317/
- Light effects on inflammatory cytokines in rheumatoid arthritis synoviocytes: https://www.ncbi.nlm.nih.gov/pubmed/19347944
- Systematic review — location-specific doses for chronic joint disorders: https://www.ncbi.nlm.nih.gov/pubmed/12775206